3 levels (cranial, middle and caudal) with grade 1 representing 1–5% emphysema, 2 = 6–25% emphysema, 3 = 26–50%, 4 = 51–75% and 5 >75% emphysema. Mean age at presentation was 40.7 (SD 5.4) years with all subjects aged 50 years or younger and 18/41 (44%) were younger than 40 years. Mean pack years cigarette smoking was 27 (19) and subjects had smoked heroin for 14.8 (6.6) years. Mean pre-bronchodilator FEV1 was 0.99 (0.52) L; 29.9 (17.6)%predicted and FEV1/FVC was 0.36 (0.13). Nine subjects had moderate (GOLD stage II), 7 severe (GOLD stage III) and 25 had very severe (GOLD stage IV) COPD. DLco was 41 (23)%predicted in the 9 subjects and alpha-1-antitrypsin level was normal in the 20 subjects who had it measured. Twenty nine CT scans were high resolution and suitable for detailed analysis. 28/29 (97%) subjects had at least grade 1 upper lobe emphysema and mean upper lobe emphysema extent (average of the 2 upper lobe scores) was 3.0 (1.4) with 15/29 (52%) subjects having grade 3 emphysema or worse. Overall emphysema extent (average of all 6 scores) was 2.5 (1.1). Moderate bronchiectasis was seen on only 3 scans and no subject had severe bronchiectasis. The other 12 CT scans could not be precisely graded but all had been reported as showing emphysema (2 mild, 2 moderate, 1 moderate to severe and 7 severe). Heroin smoking is associated with very early onset severe COPD with predominant emphysema. This is an important public health message needing dissemination to heroin smokers, drug service workers and healthcare professionals.

**P126**

THE PREVALENCE OF SELF REPORTED RESPIRATORY Symptoms AND Diagnoses AMONGST Patients ATTENDING A Drug Dependance CLINIC

1A Tridimas, 1T Archer, 2J Rehman, S Oelbaum, H Burhan; 1Royal Liverpool University Hospital, Liverpool, United Kingdom; 2Addaction, Liverpool, United Kingdom

Background The prevalence and characteristics of respiratory symptoms and diagnoses in a drug dependent population have not been characterised.

Methods A prospective cross-sectional study of all clients attending a UK drug treatment service between January 2012 and March 2013.

Results A total of 62 clients completed questionnaires. 44 (71%) smoked cigarettes, 39 (63%) tobacco (mean pack years (SD) combined cigarettes/tobacco 23.5 (25)), 40 (65%) marijuana, 54 (87%) crack and 57 (92%) heroin. 26 clients (42%) injected heroin. Only 17 (24%) reported having had spirometry. Clients were divided into tertiles (‘heavy’, ‘moderate’ and ‘mild’) exposure to smoked tobacco and drugs according to total smoking history (combined pack years, joints/day years, rocks/day years and bags/day years respectively for tobacco, marijuana, crack and heroin). There were no statistically significant differences between groups - See Table 1.

Conclusions The majority of the clients reported at least one symptom suggestive of airways disease. A larger study incorporating spirometry based at drug clinics may help to diagnose, and thereby facilitate effective treatment, of underlying COPD in this population. Early diagnosis and treatment could reduce illness within this population, prevent admissions and lead to significant savings in NHS spending.

**REFERENCES**


**P127**

RADIOLOGICAL DIAGNOSIS OF EMPHYSEMA, PNEUMOTHORAX AND BULLAE: CASE FOR TOBACCO AND CANNABIS SMOKING HISTORIES

B Selvarajah, R Collier, C Cleland, P Beddoes, S Howling, L Jones, R Collier; Whittington Health, London, UK

Background: Smoking is the leading cause of preventable death globally and has a significant impact on the health of smokers and non-smokers. Cannabis smoking has become widespread and is increasingly being used in combination with tobacco.

Methods: Questionnaires were administered to all clients attending a local drug treatment service in 2013. Data was collected on tobacco and cannabis smoking and the presence of symptoms suggestive of airways disease.

Results: A total of 62 clients completed questionnaires. 44 (71%) smoked cigarettes, 39 (63%) tobacco (mean pack years (SD) combined cigarettes/tobacco 23.5 (25)), 40 (65%) marijuana, 54 (87%) crack and 57 (92%) heroin. 26 clients (42%) injected heroin. Only 17 (24%) reported having had spirometry. Clients were divided into tertiles (‘heavy’, ‘moderate’ and ‘mild’) exposure to smoked tobacco and drugs according to total smoking history (combined pack years, joints/day years, rocks/day years and bags/day years respectively for tobacco, marijuana, crack and heroin). There were no statistically significant differences between groups - See Table 1.

Conclusions: The majority of the clients reported at least one symptom suggestive of airways disease. A larger study incorporating spirometry based at drug clinics may help to diagnose, and thereby facilitate effective treatment, of underlying COPD in this population. Early diagnosis and treatment could reduce illness within this population, prevent admissions and lead to significant savings in NHS spending.

**REFERENCES**


were no cannabis-only smokers and only 6/62 (9.7%) were never-smokers (tobacco&cannabis).
56/62 (90%) abnormal HRCTs were in ex/current tobacco smokers and 27/62 (44%) were in current tobacco&cannabis smokers. There was a higher prevalence of pneumothoraces and bullae with a cannabis and tobacco smoking history than for tobacco alone but this was not statistically significant different (chi-squared STATA) (Table1).

Conclusion More than half of tobacco smokers with abnormal HRCTs also had a history of previous and current cannabis smoking. Despite these findings 25% of patients with abnormal HRCTs had no documentation regarding cannabis smoking. This population of ≤50 years olds with abnormal HRCTs did not smoke cannabis without tobacco. While not statistically significant, bullae and pneumothoraces were more frequently observed in patients who smoked tobacco with cannabis compared to tobacco alone. Larger studies are needed to further understand the additive effect of cannabis smoking to tobacco-induced lung damage. These studies will require systematic recording of both tobacco and cannabis smoking histories.

Abstract P127 Table 1. The association between specific CT findings and tobacco smoking history (without a cannabis smoking history), compared to cannabis and tobacco smoking history.

<table>
<thead>
<tr>
<th>Emphysema (%)</th>
<th>Previous/current pneumothorax (%)</th>
<th>Bullae (%)</th>
<th>&gt;1 abnormality (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Previous/current tobacco smoking history</td>
<td>29/42 (67.4)</td>
<td>19/42 (44.1)</td>
<td>25/42 (58.1)</td>
</tr>
<tr>
<td>Previous/current tobacco smoking history (n = 43)</td>
<td>10/13 (76.9)</td>
<td>4/13 (30.8)</td>
<td>5/13 (38.5)</td>
</tr>
</tbody>
</table>

**COPD exacerbations: the heart of the matter**

P128 CARDIOVASCULAR EFFECTS OF STATIN THERAPY ON ARTERIAL STIFFNESS IN PATIENTS WITH COPD: A DOUBLE BLIND RANDOMISED CONTROLLED TRIAL

1M John, 2JR Cockcroft, 3TM McKeever, 4DJ Shale, 5JG Thornton, 1AJ Knox, 1CE Bolton, 1Nottingham Respiratory Research Unit, Nottingham, UK; 2Wales Heart Research Institute, Cardiff, UK; 3Royal Brompton & Harefield NHS Foundation Trust, London, UK; 4Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK; 5University College London & Royal Free Hospital NHS Foundation Trust, London, UK; 6Nottingham Respiratory Research Unit, University of Nottingham, Nottingham, UK; 7Edinburgh University, Edinburgh, UK; 8University of Liverpool, Liverpool, UK; 9GlaxoSmithKline, King of Prussia, USA

Background As cardiovascular disease is a comorbidity and major cause of death in patients with COPD, primary preventative strategies are required. Arterial stiffness, as measured by aortic pulse wave velocity (PWV) is increased in patients with COPD1, and is an independent predictor of cardiovascular risk2, which is modifiable over the short term. We hypothesised that aortic PWV, would be reduced by six weeks treatment of simvastatin 20mg once daily compared to placebo in selected patients with COPD without concurrent heart disease, diabetes or hypercholesterolemia.

Methods Clinically stable patients with confirmed COPD were recruited and randomised to either simvastatin 20mg od (active) or placebo in double blinded fashion. Aortic PWV, blood pressure, spirometry, six minute walking distance, and lipids were measured pre- and post- 6 weeks treatment. Primary analysis compared PWV between groups. A predefined subgroup analysis compared those with a baseline PWV≥10m/s.

Results The patients were well matched for age, sex, smoking and lung function; active, n = 33 and placebo, n = 37. The recruitment target was met. Compliance was high with the active group achieving significantly lower total cholesterol - between arms mean (95% CI): -1.1 (-1.3,-0.8 mmol/L, p < 0.001. There was no significant change in aortic PWV after treatment in the active compared to placebo group: -0.7 (-1.8, 0.5)m/s, p = 0.24. In the subgroup with aortic PWV≥10m/s, n = 22, aortic PWV improved in the active arm compared to placebo: -2.8 (-5.2, -0.3)m/s, p = 0.03. This latter difference remained statistically significant after adjusting for age and sex. Blood pressure, lung function and six minute walking distance did not change.

Conclusions In this pilot study, despite a significant reduction in total cholesterol there was no improvement in aortic PWV in patients with COPD taking simvastatin 20mg compared to placebo over 6 weeks. The positive findings in the subgroup with a higher baseline aortic PWV warrants further studies in high risk patients to confirm the impact of statin use on the cardiovascular outcome of COPD.

Trial reference: NCT01151306

Supported by NHRI RfPB grant

REFERENCES

**P129 SKELETAL MUSCLE WEAKNESS, NOT ARTERIAL STIFFNESS, DIFFERS ACCORDING TO GOLD GROUP IN COPD**

1M Fisk, 2N Gale, 3D Mohan, 4MN Marchong, 5J Forman, 6DA Lomas, 7W MacNee, 8CM Calverley, 9R Tal-Singer, 1IB Wilkinson, 2N Gale, 3D Mohan, 4MN Marchong, 5J Forman, 6DA Lomas, 7W MacNee, 8CM Calverley, 9R Tal-Singer

Introduction In the GOLD 2011 COPD classification, patients in Group D are considered to be at highest risk of mortality, due to airflow limitation and exacerbations and also to be most symptomatic. Skeletal muscle weakness and cardiovascular disease are associated with mortality in patients with COPD and elderly people per se. We hypothesised that GOLD D patients would have more severe extra-pulmonary manifestations of COPD than A-C.

Objectives To measure skeletal muscle weakness and arterial stiffness (an independent predictor of cardiovascular risk) in the ERICA (Evaluating the Role of Inflammation in Chronic Airways...